FDA approves drug for infantile-onset Niemann-Pick type C after analysis finds longer survival
Researchers at the National Institutes of Health (NIH) and their collaborators at Beren Therapeutics, Thousand Oaks, California, have developed a treatment for infants with Niemann-Pick type C (NPC) disease, which is a rare and rapidly fatal pediatric neurodegenerative disorder. The drug, known as cyclodextrin (brand name Adrabetadex), extended the survival of participants with NPC in a large,…
The FDA has approved a drug called cyclodextrin, marketed under the brand name Adrabetadex, for infants with Niemann-Pick type C (NPC), a rare and rapidly fatal pediatric neurodegenerative disorder. This approval follows a large, international clinical trial that demonstrated the drug extended the survival of participants with NPC.
The drug's development began 20 years ago, with foundational research conducted at the National Institutes of Health (NIH). The drug works by directly addressing the issues caused by NPC, which is due to a mutation in the NPC1 gene that leads to a deficiency of a protein facilitating regular transport of lipids and cholesterol through cells.
This results in an abnormal buildup of these substances within cells, causing progressive neurological decline and premature death. The NIH has been committed to basic research, careful study of patients over time, and strong partnerships, playing a crucial role in creating the first FDA-approved treatment for infants with NPC. This approval provides new hope to families impacted by this devastating disease.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.